Featured Education

soho-2024-enduring-banner-445x250-02-02-02_1727985795
p24011-lms-thumb_1726675197
P23033 LMS Thumb
p24034-obesity-aafp-lms-thumbnail-445x250px_1723738749
lms-thumbnail-445-x-250_1720799794
Exploring the Intricacies of Red Blood Cells

On Demand Activities

Therapeutics Areas
Learner Specialties
Expires After
The Evolution of HCT, Part 5: Shared Care
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 5 in a 5-part series, exploring how shared and coordinated care between transplant centers and hematology/oncology practices can help overcome barriers to HCT and improve patient outcomes and experience.
Dermatology Dialogues | Gaining and Maintaining Flare Control in Moderate-to-Severe Atopic Dermatitis: Enhancing Patient Quality of Life
This 4 part-15 minute segmented vodcast/podcast will unite dermatology and allergy clinicians, who provide care for patients with moderate-to-severe atopic dermatitis (M-S AD).
Understanding the Impact of Weight on T2D Outcomes
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Build Your Own Case Study | Redefining MASLD/MASH Care: Personalized Strategies for Assessment, Diagnosis and Management
Health Care Providers (HCPs) in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) and its associated risk factors, as well as feel confident around how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.
Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care
In this third episode, “Taking a Team Approach: Community-based Practices at the Forefront of NHL and HL Care,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” join expert faculty and special guest, Caitlin Murphy, DNP to discuss community-based practices for the treatment of NHL and HL. This episode will focus on how to best evaluate patients for and increase participation in clinical trials. Additional conversations will revolve around assessing patient quality of life, recognizing social determinants of health that impact patient care, and recognizing healthcare barriers and inequities in your own patient population. This episode will conclude with a conversation about misperceptions for CAR T-cell therapy and how to best coordinate care for patients receiving either CAR T-cell therapy or bispecific antibody therapy.
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Scroll to Top